Home
Alentis Therapeutics AG

Alentis Therapeutics AG Market Share Analysis for June 2026

"Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotechnology company developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression... Mehr

Industry: N/A

Domainalentis.ch

Year Founded2019

Employees51 - 200

Annual Revenue$25M - $50M

Alentis Therapeutics AG

Alentis Therapeutics AG (including company regionals)

alentis.ch

See more website traffic and engagement information

Alentis Therapeutics AG Revenue up to June 2026 is 25M - 50M

revenue generated by Alentis Therapeutics AG top domains

Alentis Therapeutics AG top domains revenue over 3 years

Revenue for Alentis Therapeutics AG top domains

alentis.ch25M - 50M

See more with Sales Intelligence

Total visits to Alentis Therapeutics AG's top domains

Understand Alentis Therapeutics AG market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alentis.ch3.9K

See more with Sales Intelligence

Avg. visit duration in Alentis Therapeutics AG's top domains

Analyze Alentis Therapeutics AG engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alentis.ch00:00:19

See more with Sales Intelligence

Avg. pageviews on Alentis Therapeutics AG's top domains

See how Alentis Therapeutics AG keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alentis.ch1.80

See more with Sales Intelligence

Alentis Therapeutics AG top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Alentis Therapeutics AG

These are the website technologies, by industry, used by Alentis Therapeutics AG top domains

Payment & Currencies (6)

Cart Functionality

Widget (4)

Twemoji

Advertising (2)

DoubleClick

Content Management System (2)

WordPress

More Technologies

5

See all

News & Signals from Alentis Therapeutics AG

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlentis Therapeutics AG hires Yoon.Mr. Yoon and Dr. Venugopal are joining Alentis' executive leadership team.

NewsAlentis Therapeutics AG hired Mark Pruzanski as Chief Executive Officer on Oct 15th '25.Basel, Switzerland - Oct 15, 2025, Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Mark Pruzanski, MD, as the company's new Chief Executive Officer.

NewsAlentis Therapeutics AG received financing of $1.4M in Series D on Nov 14th '24.This week, Alentis Therapeutics, a Swiss biotech firm, announced a successful Series D financing round, raising a total of 1.4 million.